New drug combo aims to outsmart lung Cancer's immune evasion

NCT ID NCT05782361

Ongoing Disease control Sponsor: Institute of Cancer Research, United Kingdom Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tests two drugs, tepotinib and pembrolizumab, together in 19 people with advanced non-small cell lung cancer. Tepotinib targets a specific gene change (MET) that can help cancer grow, while pembrolizumab boosts the immune system. The goal is to see if this combination can shrink tumors in patients whose cancers don't respond to immunotherapy alone.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: tepotinib and pembrolizumab
What this could lead to: If it works, this combination could offer a new treatment option for non-small cell lung cancer patients who don't respond to immunotherapy alone.
What could go wrong: This is a very early phase 1 trial with only 19 participants, so results may not apply widely. The combination may cause side effects or fail to improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer lung neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED CANCER NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

DDU, Royal Marsden Hospital NHS Foundation Trust

Sutton, Surrey, SM2 5PT, United Kingdom
Lung Unit, Royal Marsden Hospital NHS Foundation Trust

London, SW3 6JJ, United Kingdom
The Christie NHS Foundation Trust

Manchester, M20 4BX, United Kingdom
University College London Hospitals NHS Foundation Trust

London, NW1 2BU, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.